Alberto Molano was born in Bogotá, Colombia. He studied medicine at Universidad del Rosario and obtained a Ph.D. in Immunology from Weill Cornell Graduate School of Medical Sciences in New York. He conducted research and authored or co-authored twenty publications on molecular and cellular immunology, autoimmunity, immunology of aging and parasite immunology.
Adverse effects are associated with poor adherence to phosphodiesterase-5 inhibitors (PDE-5I) as treatment for patients with pulmonary arterial hypertension (PAH) treated via an integrated care model at an academic ... Read more
New data support the safety and effectiveness of TIVUS (therapeutic intra-vascular ultrasound) for patients with pulmonary arterial hypertension (PAH) on a stable treatment regimen. The data were recently presented at ... Read more
Dacomitinib, a medicine recently approved by the U.S. Food and Drug Administration for the treatment of certain forms of lung cancer, showed promising therapeutic effects in two animal models ... Read more
Teva Pharmaceutical Industries announced the launch of a generic version of Adcirca (tadalafil) under the brand name ALYQ for the treatment of pulmonary arterial hypertension (PAH) in the United States. PAH ... Read more